Provided by Tiger Trade Technology Pte. Ltd.

Intensity Therapeutics, Inc.

5.40
+0.08001.50%
Volume:13.62K
Turnover:72.88K
Market Cap:13.68M
PE:-0.63
High:5.42
Open:5.21
Low:5.20
Close:5.32
52wk High:48.56
52wk Low:4.63
Shares:2.53M
Float Shares:2.32M
Volume Ratio:2.76
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.5567
EPS(LYR):-29.2443
ROE:-156.90%
ROA:-79.25%
PB:1.15
PE(LYR):-0.18

Loading ...

Company Profile

Company Name:
Intensity Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
6
Office Location:
1 Enterprise Drive,Suite 430,Shelton,Connecticut,United States
Zip Code:
06484-4779
Fax:
203 557 3023
Introduction:
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Directors

Name
Position
Lewis H. Bender
Director,President,Chief Executive Officer and Chairman
Daniel Donovan
Independent Director
Emer Leahy
Independent Director
Mark A. Goldberg
Independent Director
Thomas I.H. Dubin
Director

Shareholders

Name
Position
Lewis H. Bender
Director,President,Chief Executive Officer and Chairman
Joseph Talamo
Chief Financial Officer
John Wesolowski
Principal Accounting Officer and Controller